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easuring
roponin Elevation After
ercutaneous Coronary Intervention
eady for Prime Time?*
eal S. Kleiman, MD
ouston, Texas
ince the description by Klein et al. (1) of unexpected rise in
lasma creatine kinase muscle-brain fraction (CK-MB)
ollowing percutaneous transluminal angioplasty, debate has
nsued concerning the mechanisms, meaning, and impor-
ance of this phenomenon. Postulated mechanisms for its
ccurrence have included transient balloon-induced isch-
mia, side branch occlusion, and embolization of platelet-
brin aggregates along with atherosclerotic debris. Data
xtracted from several large databases have indicated that
hen levels of CK-MB release are high, the relationship
ith ensuing events, particularly mortality, is clear; the
argest of these databases (those with the most statistical
ower) have also indicated that the long-term relative risk of
ortality is increased even when the levels of enzyme
levation are relatively low (2). A study by Kong et al. (3)
uggested that the diffuse nature of microinfarction repre-
ented by CK-MB elevation might provide the substrate for
udden cardiac death as a mechanism of mortality. Other
uthors, however, have suggested that CK-MB elevation
ay be most important as a covariate of lesion complexity
nd the extent of coronary atherosclerosis (4). Now that the
roponins and other markers of myocardial necrosis have
ecome available, similar questions about their importance
n the prognostication of patients following percutaneous
rocedures are arising.
See page 1765
Recent evidence, obtained using diffusion-weighted mag-
etic resonance image scanning has confirmed the near
niversal finding that CK-MB and troponin elevations are
ssociated with areas of reduced perfusion consistent with
yocardial infarction (5,6). Few observers would seriously
rgue that release of either marker is not associated with
nfarction at the cellular level. Of course, the clinical
ignificance of these events needs to be resolved. In the age
f near-universal stenting, more complete revascularization,
nd low restenosis rates, how important is an infarction of 3
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thet
merican College of Cardiology.
From the Methodist DeBakey Heart Center, Houston, Texas.o 4 g of myocardial tissue, or how critical is a marker of
laque instability once the plaque is “sealed” with a stent?
In this issue of the Journal, Prasad et al. (7) examine the
ignificance of isolated elevation in plasma troponin T after
ncomplicated percutaneous cardiac intervention (PCI).
mong 4,760 patients undergoing PCI, 1,949 had normal
aseline CK-MB and troponin T and had their post-
rocedure troponin levels evaluated; 383 (19.6%) of these
atients had elevation in troponin T but not CK-MB after
he procedure. This occurred despite nearly 50% use of
lycoprotein (GP) IIb/IIIa antagonists and 90% stent place-
ent. As expected, the degree of underlying illness in these
atients was greater than in patients in whom circulating
roponin T was undetectable. The number of in-hospital
vents was relatively small, and only at about the first year
as the rate of death or myocardial infarction observed to be
igher in the troponin-positive group. At 3 years, mortality
n this seemingly low-risk group of patients was 13%,
ompared with 7% in patients without troponin T elevation
partial hazard ratio 1.2, 95% confidence interval 1.02 to
.40). Among the variables studied, troponin T elevation
as found to be an independent predictor of long-term
ortality. Commonly quoted rates of myocardial infarction
fter PCI, as defined using CK-MB, range from 6% to 10%,
epending on the underlying risk of the patient population.
he data of Prasad et al. (7) indicate that infarction (based
n European Society of Cardiology/American College of
ardiology standards, which include troponin elevation [8])
ccurs in an additional 20% of patients. These figures are
oncordant with observations made in multicenter registries
EVENT [A Multicenter Registry for the Evaluation of
rug Eluting Stents and Ischemic Events] Investigators,
006). Clearly, myocardial infarction after PCI is more
ommon than is readily believed. As the number of markers
vailable to detect myocyte injury continues to grow, and as
he sensitivity for detecting them increases, the observed
ates will likely increase.
What do these findings mean? The answer is 2-fold.
irst, it must be recognized that clinical events continue to
ccur after patients who have had successful PCI are
ischarged from the hospital. Although hospital mortality is
ow, mortality continues to accrue after hospital discharge.
he e-Cypher Investigators recently reported that among a
road population of more than 14,000 patients undergoing
lacement of a sirolimus-eluting stent in late 2004 and
005, mortality rose from 0.6% at 30 days to 1.4% at 6
onths and 2.2% at 1 year (9). Although CK-MB elevation
as been a useful surrogate for mortality, not all deaths
uring follow-up can be predicted on the basis of CK-MB
levation; some authors have argued that rather than a
urrogate, it should be viewed as one of many risk factors
4). Because the attributable risk associated with CK-MB
levation greater than 3-fold is approximately 14% (10), it is
lmost certain that additional factors are involved. Addi-
ional markers may be useful to help refine risk estimates.
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Editorial Comment November 7, 2006:1771–3The second part of the answer lies in the additional
rognostic information obtained from examining additional
arkers after PCI. In principle, it is likely that an associa-
ion can be found between elevation of any abnormal
rotein in the blood after PCI and worse outcomes. Most
tudies that have examined the significance of troponin
levation were relatively small and did not include long term
ollow-up. In the largest of these studies, Kini et al. (11)
bserved that approximately 25% of patients with normal
ost-procedure CK-MB had elevations in the levels of
roponin I. In contrast with the present study, follow-up
as for 12 months; CK-MB was the most powerful predic-
or of events during this period. Unlike the observations
ade by Prasad et al. (7), only elevations of troponin
xceeding 5-fold predicted events during follow-up. Inter-
stingly, the estimated hazard ratios for troponin I elevation
1.1 to 1.4, depending on the level of elevation) were very
imilar to those of Prasad et al. (7).
At the current time, the findings of Prasad et al. (7)
hould be viewed as proof of principle rather than as a
ictum for altering practice. Over the last 15 years, a wealth
f information has accumulated concerning the prognostic
nformation surrounding CK-MB elevation. This body of
nowledge does not yet exist for the troponins. The latest
teration of American College of Cardiology/American
eart Association guidelines for PCI now assigns a class I
ndication for determination of CK-MB or troponin after
CI complicated by evidence of ischemia and a class IIa
ndication for routine collection of either marker (12).
uring preparation for a number of clinical trials and
egistries, we have learned that about half of the PCI centers
n the U.S. have adopted the latter practice. However,
ecause there is no specific therapy for such patients (other
han aspirin, clopidogrel, and statins, which are routinely
sed in post-PCI patients anyway) the utility of the test for
linical decision making rather than for informational pur-
oses remains in question. The recognition of CK-MB
levation as an important prognostic indicator, and its
cceptance as a surrogate for catastrophic clinical events was
nstrumental in the development of “adjunctive” therapies
esigned to reduce the rate of periprocedural infarction.
ost hoc analyses of these treatments has confirmed the
elationship between reductions in enzyme release with
eduction in mortality (13,14). Perhaps the recognition that
roponin T elevations occur after otherwise uncomplicated
rocedures and are associated with a 20% increase in
ong-term mortality ought to prompt the development of
ew strategies, both short- and long-term. As has been the
ase with CK-MB, it is likely that there will be controversy
s to whether the association is causal or is an index of
nderlying risk. Several steps are needed to address this
ssue. First, the findings reported in the present study need
o be replicated. Data accumulated from large registries of
tent implantation as well as upcoming stent trials offer the
pportunity to confirm or refute these findings. Because
K-MB is usually collected in these studies, includingroponin, determination would involve little additional ef-
ort. Second, new trials of therapies designed to reduce
eriprocedural infarction (defined using CK-MB) should
lso include data collection concerning the frequency of
roponin elevation and the effect of the treatment on it.
orrelation of clinical outcomes with changes in troponin-
efined infarction should follow. Such observations would
e useful in determining whether troponin is a useful
urrogate for mortality after PCI. Formal rules are evolving
or acceptance of an end point as a valid surrogate (15), and
hese will need to be applied to newly recognized biomar-
ers.
At least one novel experimental use also exists for
roponin measurement after PCI. Data from a number of
ources indicate that endothelialization is delayed after
lacement of drug-eluting stents compared with bare-metal
tents (16); there has been concern about the effect of this
henomenon on subacute and late stent thrombosis (17). It
s also possible that delayed endothelialization exposes the
ecipients of drug-eluting stents to a longer risk period for
icroinfarction. Although periprocedural infarction is gen-
rally stated to occur within 24 h after stent placement, it
s worth noting that measurement of CK-MB is rarely
erformed after this period. Current assessments are inad-
quate to test this hypothesis, and asking patients to return
o the hospital for daily measurements of CK-MB is clearly
mpractical. Because troponin levels remain elevated in the
lood for days to weeks, 1 or 2 late measurements of
roponin several days after hospital discharge might help
hed light on this situation. All these steps would be useful
n determining whether troponin is useful as a surrogate for
ortality after PCI.
The present report should help refocus the stage light on
ost-procedural infarction. We now know that it happens,
ven in the context of modern techniques (i.e., well-
eveloped technical skills, aggressive use of GP IIb/IIIa
ntagonists, clopidogrel, and modern stents). If we are to
ontinue to reduce the long-term morbidity and mortality in
atients who have had interventions, we will need to
ecognize that there are new markers of risk that merit our
ttention.
eprint requests and correspondence: Dr. Neal S. Kleiman,
ethodist DeBakey Heart Center, 6565 Fannin MS F-1090,
ouston, Texas 77030. E-mail: nkleiman@tmh.tmc.edu.
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